4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5h-pyrimido [4, 5-B[1, 4] diazepin2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases PLK1 to PLK4 for the treatment of proliferative diseases

Details for Australian Patent Application No. 2008287339 (hide)

International Classifications

Event Publications

4 March 2010 PCT application entered the National Phase

PCT publication WO2009/023269 Priority application(s): WO2009/023269

17 June 2010 Amendment Made

The nature of the amendment is: Amend the invention title to read 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido [4, 5-b[1, 4] diazepin2-ylamino)-3-methoxybenzamide Derivatives as Inhibitors of the Human Protein Kinases PLK1 to PLK4 for the Treatment of Proliferative Diseases

15 July 2010 Corrigenda

Amendments - Amendments Made Under the name Vertex Pharmaceuticals Incorporated, Application No. 2008287339, under INID (54), correct the invention title to 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido [4, 5-b][1, 4] diazepin2-ylamino)-3-methoxybenzamide Derivatives as Inhibitors of the Human Protein Kinases PLK1 to PLK4 for the Treatment of Proliferative Diseases

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.